Arakoda

The dosage of tafenoquine depends entirely on the reason for prescription. It is vital to follow the specific instructions provided by your healthcare provider.

Radical Cure of P. vivax (Krintafel)

• Standard Dose: The recommended dose for adults is a single 300 mg dose, administered as two 150 mg tablets taken together on a single day.
• Timing: This dose is typically given on the first or second day of the initial treatment for the acute malaria infection (usually alongside a blood-stage antimalarial like chloroquine).

Malaria Prophylaxis (Arakoda)

• Loading Dose: 200 mg (two 100 mg tablets) once daily for three consecutive days before traveling to the malaria-endemic area.
• Maintenance Dose: 200 mg (two 100 mg tablets) once weekly while in the endemic area. The first weekly dose should start 7 days after the last loading dose.
• Terminal Dose: A single 200 mg dose (two 100 mg tablets) taken in the week after returning from the endemic area.

• Radical Cure (Krintafel): In 2021, the FDA expanded the approval of Krintafel to include pediatric patients aged 2 years and older (weighing at least 10 kg). The dosage is weight-based. For example, children weighing 10-20 kg may receive a single 100 mg dose, while those over 35 kg receive the adult 300 mg dose. Specific pediatric tablets (50 mg) may be available for this population.
• Prophylaxis (Arakoda): Tafenoquine (Arakoda) is currently NOT approved for use in pediatric patients under the age of 18 for the prevention of malaria.

Renal Impairment

Specific dosage adjustments for patients with renal (kidney) impairment have not been established in clinical trials. However, because renal excretion of the unchanged drug is low, significant changes in exposure are not expected. Healthcare providers will monitor these patients closely for potential side effects.

Hepatic Impairment

The effect of hepatic (liver) impairment on the pharmacokinetics of tafenoquine has not been fully studied. Since the drug is slowly metabolized, caution is advised when prescribing to patients with severe liver disease.

Elderly Patients

Clinical trials did not include enough participants aged 65 and over to determine if they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

• With Food: Tafenoquine MUST be taken with food. Taking it on an empty stomach significantly reduces the amount of medicine absorbed by your body, which may make the treatment fail.
• Swallow Whole: Tablets should be swallowed whole. For pediatric patients who cannot swallow tablets, your healthcare provider may provide instructions on crushing tablets and mixing them with applesauce or yogurt.
• Consistency: For prophylaxis, take your weekly dose on the same day each week to maintain steady levels in your bloodstream.
• Storage: Store at room temperature (20°C to 25°C or 68°F to 77°F) in the original blister packaging to protect the tablets from moisture.

• Radical Cure: If you miss the single dose of Krintafel, contact your doctor immediately. The timing relative to your other malaria medications is important.
• Prophylaxis (Loading): If you miss one of the three loading doses, take it as soon as you remember and then continue the daily schedule. This may delay your travel start or your transition to the weekly dose.
• Prophylaxis (Weekly): If you miss a weekly dose, take it as soon as you remember, provided it is not almost time for the next dose. Do not double the dose to catch up.

Signs of overdose may include severe nausea, vomiting, or symptoms of methemoglobinemia (such as bluish skin, headache, or shortness of breath). If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately. Because of the drug's long half-life, symptoms may persist or appear days after the overdose.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients tolerate tafenoquine well, but some may experience mild to moderate side effects. Common reactions reported in clinical trials include:

• Dizziness: A feeling of lightheadedness or spinning (vertigo). This is usually transient but can be bothersome during the first 24-48 hours.
• Headache: Mild to moderate head pain is one of the most frequently cited side effects.
• Gastrointestinal Issues: This includes nausea, vomiting, and abdominal pain. Taking the medication with a full meal significantly reduces the likelihood and severity of these symptoms.
• Abnormal Dreams: Some patients report vivid or unusual dreams, particularly with the weekly prophylaxis regimen.

• Insomnia: Difficulty falling or staying asleep.
• Anxiety: Feelings of nervousness or restlessness.
• Increased Hemoglobin: In some patients without G6PD deficiency, a slight, temporary increase in hemoglobin may occur.
• Diarrhea: Loose stools occurring shortly after administration.
• Back Pain: Generalized discomfort in the lower or upper back region.

• Vortex Keratopathy: This is a condition where microscopic deposits form on the cornea of the eye. While more common with long-term use of related drugs like chloroquine, it has been observed rarely with tafenoquine. It typically does not affect vision and resolves after the drug is stopped.
• Methemoglobinemia: A condition where the blood cannot carry oxygen effectively. Symptoms include a bluish tint to the lips or fingernails (cyanosis).
• Psychosis: In very rare cases, particularly in those with a history of psychiatric illness, tafenoquine may trigger hallucinations or severe confusion.

> Warning: Stop taking Tafenoquine and call your doctor immediately if you experience any of these.

• Hemolytic Anemia: This is the most serious risk associated with tafenoquine. It occurs almost exclusively in individuals with G6PD deficiency. Symptoms include extreme tiredness, pale skin, dark-colored urine (tea-colored), yellowing of the skin or eyes (jaundice), and shortness of breath. This condition involves the rapid destruction of red blood cells and can be life-threatening.
• Severe Hypersensitivity: Signs of an allergic reaction include hives, swelling of the face, lips, or tongue, and difficulty breathing.
• Severe Psychiatric Changes: If you experience thoughts of self-harm, severe depression, or see/hear things that are not there (hallucinations), seek help immediately.
• Signs of Methemoglobinemia: If your skin, lips, or nail beds turn blue or grey, or if you feel unusually fatigued or short of breath, you may require emergency treatment with methylene blue.

Because tafenoquine remains in the body for several months after the last dose, side effects can theoretically persist or emerge long after treatment ends. Long-term use (beyond 6 months of prophylaxis) has not been extensively studied, and the risk of cumulative toxicity, particularly to the eyes (corneal deposits) or the blood system, remains a point of clinical monitoring for those on extended travel assignments.

No FDA black box warnings for Tafenoquine. However, the FDA-approved labeling contains a 'Contraindication' and 'Warning' section that carries similar clinical weight regarding G6PD deficiency. The labeling mandates that all patients must be screened for G6PD deficiency using a quantitative test before starting tafenoquine. This is because the risk of hemolytic anemia in G6PD-deficient individuals is considered an absolute safety barrier.

Report any unusual symptoms to your healthcare provider. Even if a symptom seems minor, the long half-life of tafenoquine means that medical observation may be necessary for an extended period.

The most critical safety factor for tafenoquine is the patient's Glucose-6-phosphate dehydrogenase (G6PD) status. G6PD is an enzyme that helps red blood cells function normally and protects them from oxidative stress. Tafenoquine causes oxidative stress; without enough G6PD, red blood cells rupture (hemolysis).

No FDA black box warnings for Tafenoquine. While it lacks a boxed warning, the requirement for G6PD testing is a 'Hard Stop' in clinical practice. Prescribing tafenoquine without a confirmed, normal quantitative G6PD test result is considered a major deviation from safety protocols.

• G6PD Deficiency and Hemolysis: Tafenoquine is strictly contraindicated in individuals with G6PD deficiency (defined as <70% of the normal enzyme activity level). Even 'intermediate' levels of G6PD activity carry a risk of hemolysis. Patients must be monitored for signs of hemolytic anemia (dark urine, jaundice) for several weeks after taking the dose due to the drug's long half-life.
• Pregnancy and Fetal Risk: Tafenoquine can cause hemolytic anemia in a G6PD-deficient fetus if taken by the mother. Because the G6PD status of a fetus cannot be determined, tafenoquine is contraindicated during pregnancy.
• Psychiatric Effects: There is a risk of psychiatric adverse reactions, including anxiety, abnormal dreams, and insomnia. Healthcare providers should exercise caution when prescribing tafenoquine to patients with a history of psychiatric disorders, such as depression or psychosis. If a patient experiences new or worsening psychiatric symptoms, the drug should be discontinued (for prophylaxis) or the patient should be monitored closely (for radical cure).
• Methemoglobinemia: Tafenoquine can cause a dose-dependent increase in methemoglobin. Patients with pre-existing methemoglobinemia or those taking other drugs that cause this condition (like lidocaine or sulfonamides) are at higher risk.
• Hypersensitivity Reactions: As with any medication, there is a risk of serious allergic reactions. Because the drug stays in the system for weeks, an allergic reaction may require prolonged treatment and observation.

• G6PD Testing: A quantitative G6PD test is mandatory before the first dose. Qualitative 'rapid' tests may not be sufficient to detect intermediate deficiency.
• Hemoglobin/Hematocrit: In patients at risk or those showing symptoms of anemia, healthcare providers may order a Complete Blood Count (CBC).
• Clinical Monitoring: Patients should be educated to monitor their urine color and skin tone for at least 3 weeks following a dose of tafenoquine.

Tafenoquine may cause dizziness or other neurological symptoms in some individuals. Patients should assess their reaction to the medication before driving, operating heavy machinery, or performing tasks that require mental alertness.

There are no specific documented interactions between tafenoquine and alcohol. However, alcohol can sometimes worsen the gastrointestinal side effects (nausea, vomiting) or dizziness associated with the drug. It is generally advisable to limit alcohol consumption while taking antimalarial medications.

For those taking tafenoquine for prophylaxis (Arakoda), if the drug must be discontinued due to side effects, the patient is no longer protected against malaria. Because the drug has a long half-life, it will remain in the system for weeks after the last dose, meaning side effects may not resolve immediately, but the concentration may eventually fall below the level needed to prevent malaria infection.

> Important: Discuss all your medical conditions with your healthcare provider before starting Tafenoquine.

• Live Vaccines (Typhoid): While not a direct chemical interaction, some antimalarials can interfere with the immune response to live oral typhoid vaccines (Vivotif). It is generally recommended to complete the vaccine series at least 3 days before starting antimalarial prophylaxis.
• Other 8-Aminoquinolines: Tafenoquine should never be used concurrently with primaquine. Both drugs cause oxidative stress and the risk of severe hemolytic anemia and methemoglobinemia would be significantly compounded.

• OCT2 and MATE Substrates: Tafenoquine inhibits the Organic Cation Transporter 2 (OCT2) and Multidrug and Toxin Extrusion (MATE) transporters. This can lead to increased blood levels of drugs that rely on these transporters for excretion.
• Metformin: Taking tafenoquine with metformin (a common diabetes medication) can increase metformin exposure. This may increase the risk of metformin-related side effects, such as lactic acidosis. Healthcare providers may need to adjust the metformin dose or monitor blood glucose more frequently.
• Dofetilide: Increased levels of dofetilide (an anti-arrhythmic) can lead to dangerous heart rhythm changes (QT prolongation).

• Antacids and H2 Blockers: While not strictly contraindicated, changes in gastric pH could theoretically affect the absorption of tafenoquine. However, the requirement to take tafenoquine with food usually mitigates this concern.
• CYP450 Substrates: Although tafenoquine is not a potent inhibitor of most CYP enzymes, caution is always warranted when combining it with drugs that have a narrow therapeutic index, such as warfarin or phenytoin, as individual variations in metabolism can occur.

• High-Fat Meals: Food is a positive 'interactor' for tafenoquine. Absorption is significantly enhanced by fat. Patients are instructed to take the dose with a substantial meal (approximately 800-1000 calories with 50 grams of fat is the clinical trial standard, though any full meal is better than none).
• Grapefruit Juice: There is no specific evidence that grapefruit juice significantly alters tafenoquine levels, but as it affects many other drugs, patients should consult their doctor.

• St. John's Wort: This herbal supplement induces several metabolic pathways. While tafenoquine metabolism is slow, St. John's Wort could theoretically reduce its effectiveness over long-term prophylaxis.
• Antioxidant Supplements: High doses of antioxidants (like Vitamin E or C) might theoretically interfere with the oxidative mechanism tafenoquine uses to kill parasites, although the clinical significance of this is unknown.

• Methemoglobin Levels: Tafenoquine will cause an increase in methemoglobin levels, which can interfere with pulse oximetry readings (showing a falsely low oxygen saturation) and may affect arterial blood gas results.
• G6PD Screening: The drug itself does not interfere with the G6PD test, but the test must be done before the drug is in the system, as a recent hemolytic event (from any cause) can lead to a false-normal G6PD result.

For each major interaction, the mechanism usually involves the inhibition of renal transporters (OCT2/MATE) or the additive effect of oxidative stress. Management typically involves dose monitoring or choosing alternative medications for the duration of the tafenoquine residence time.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Conditions where Tafenoquine must NEVER be used include:

• G6PD Deficiency: This is the most critical contraindication. Individuals with G6PD activity levels below 70% of the normal mean are at high risk for acute hemolytic anemia. This is due to the drug's 8-aminoquinoline structure, which induces oxidative stress that G6PD-deficient red blood cells cannot survive.
• Pregnancy: Tafenoquine is contraindicated in pregnant women because the G6PD status of the fetus cannot be verified. If the fetus is G6PD-deficient, the drug could cause life-threatening hemolysis in utero.
• Breastfeeding (when infant status is unknown): Tafenoquine should not be taken by breastfeeding women unless the infant has been tested and confirmed to have normal G6PD levels. The drug passes into breast milk and can cause hemolysis in a G6PD-deficient nursing infant.
• Hypersensitivity: Any patient with a known severe allergy to tafenoquine, primaquine, or any other 8-aminoquinoline must avoid this medication.

Conditions requiring careful risk-benefit analysis:

• Psychiatric Disorders: Patients with a history of psychosis or severe depression should be treated with caution, as tafenoquine has been associated with neuropsychiatric adverse events.
• Pre-existing Anemia: Patients with low hemoglobin levels from other causes (like sickle cell disease or iron deficiency) may have less reserve if mild hemolysis occurs.
• Severe Renal or Hepatic Impairment: Due to the lack of extensive data in these populations, healthcare providers may prefer alternative antimalarials with shorter half-lives.

There is a high likelihood of cross-sensitivity between tafenoquine and other 8-aminoquinolines. If a patient has had a severe reaction to primaquine, they should not be prescribed tafenoquine. There is no known cross-sensitivity with other antimalarial classes like artemisinins or quinolines (like quinine or chloroquine), though the underlying G6PD risk remains relevant for several of these.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Tafenoquine.

Tafenoquine is classified as a risk to the fetus. According to the FDA-approved labeling, the use of tafenoquine during pregnancy is contraindicated. The primary concern is not necessarily direct teratogenicity (birth defects), although data is limited, but rather the risk of hemolytic anemia in the fetus. Because fetal G6PD levels cannot be determined safely, and the drug remains in the mother's system for months, any woman of reproductive potential should have a pregnancy test before starting the drug and use effective contraception for 3 months after the last dose.

Tafenoquine is excreted in human breast milk. The amount an infant receives is sufficient to cause oxidative stress. Therefore, a woman should not breastfeed while taking tafenoquine—and for 3 months after the last dose—unless the infant is confirmed by a quantitative test to have normal G6PD activity. If the infant's G6PD status is unknown or deficient, breastfeeding must be avoided to prevent the risk of hemolytic anemia in the child.

• Radical Cure: Krintafel is approved for children as young as 2 years old, provided they weigh at least 10 kg. Clinical trials showed that the safety and efficacy profile in children is similar to that in adults, though weight-based dosing is essential.
• Prophylaxis: Arakoda is not approved for use in individuals under 18 years of age. Travelers seeking malaria prevention for children should discuss alternative options like atovaquone/proguanil or mefloquine with a travel medicine specialist.

Clinical studies of tafenoquine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, since elderly patients are more likely to have decreased renal or hepatic function and may be taking medications that interact with OCT2 transporters (like metformin), healthcare providers should use caution and perform thorough baseline screenings.

In patients with mild to moderate renal impairment, no dose adjustment is typically required. However, for those with severe renal impairment or end-stage renal disease, data is lacking. Because the drug is not primarily cleared by the kidneys, the risk of accumulation is lower than with other drugs, but clinical monitoring for side effects is still recommended.

Tafenoquine has not been studied in patients with significant hepatic impairment. While the liver is not the primary route of rapid elimination, it is involved in the slow metabolism of the drug. Healthcare providers should weigh the risks and benefits carefully in patients with Child-Pugh Class B or C cirrhosis.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Tafenoquine is an 8-aminoquinoline with activity against all stages of the Plasmodium vivax life cycle and the pre-erythrocytic and erythrocytic stages of Plasmodium falciparum. Its primary clinical value lies in its 'hypnozoitocidal' activity—the ability to kill dormant liver-stage parasites. The exact molecular target is still a subject of research, but it is known to interfere with the parasite's mitochondria. It disrupts the membrane potential and induces the production of reactive oxygen species (ROS), leading to oxidative damage that the parasite cannot repair. Unlike some other antimalarials, tafenoquine also has gametocytocidal activity, meaning it can potentially reduce malaria transmission by killing the forms of the parasite that infect mosquitoes.

The pharmacodynamics of tafenoquine are characterized by its long-lasting effect. A single 300 mg dose provides enough exposure to eliminate P. vivax hypnozoites in most patients. The relationship between dose and response is well-established; lower doses are associated with a higher risk of malaria relapse. There is no evidence of significant QT interval prolongation at therapeutic doses, which is a safety advantage over some other antimalarial drugs.

| Parameter | Value |

|---|---|

| Bioavailability | Increases ~40% with high-fat food |

| Protein Binding | >99.5% (primarily to albumin) |

| Half-life | 14 to 17 days |

| Tmax | 12 to 15 hours |

| Metabolism | Minimal (slow non-CYP mediated) |

| Excretion | Primarily Fecal (slow) |

• Molecular Formula: C24H28F3N3O3
• Molecular Weight: 463.49 g/mol
• Solubility: Highly lipophilic; poorly soluble in water.
• Structure: It consists of an 8-aminoquinoline core with a side chain containing a fluorinated phenoxy group, which enhances its metabolic stability and extends its half-life compared to its predecessor, primaquine.

Tafenoquine is classified as an antimalarial agent, specifically within the 8-aminoquinoline subclass. It is the first drug in over 60 years to be approved for the radical cure of P. vivax malaria, providing a long-acting alternative to primaquine.